Skip to content
DataLookout
Menu

NCT06613360

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 20 → 24 locations
    • Site contacts updated at 1 of 24 sites
  2. Notable Eligibility criteria expanded, about 31 words
    • Study sites: 20 to 24
  3. Minor Trial sites expanded: 17 → 20 locationsv12
  4. Minor Study sites: 15 to 17v11
  5. Minor Study sites: 14 to 15v10
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 12 to 14v9
  2. Notable Eligibility criteria expanded, about 6 words
    • Study sites: 11 to 12
    v8
  3. Minor Study sites: 9 to 11v7
  4. Minor Study sites: 3 to 9
    • Start date changed from estimate of Jan 2025 to Jan 21, 2025
    v6
  5. Minor Study sites: 2 to 3
    • Start date: Dec 2024 to Jan 2025
    v5
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date: Nov 2024 to Dec 2024
    v4
  7. Minor Study title expanded, about 2 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and tolerability
Timeframe: 48 weeks

Secondary (3)

Pharmacokinetics
Immunogenicity
Pharmacodynamics-related biomarker

Arms and interventions

Part A Dose EscalationExperimental

Patients with SLE treated with CLN-978 in dose escalation cohorts

Part B Further Dose EvaluationExperimental

Further evaluation of CLN-978 treatment of patients with SLE

Drugs: CLN-978

Sites

24 sites in 9 countries

United States 12, France 3, Australia 2, Romania 2, Bulgaria 1, Georgia 1, Germany 1, Moldova 1, Spain 1